US FDA approves Sanofi's wearable injector form of blood cancer drug

Key facts

• The U.S. FDA approved Sanofi's Sarclisa in a wearable injector form.
• The drug is for patients with multiple myeloma, a rare blood cancer.
• The wearable injector allows for subcutaneous delivery, reducing infusion center time.
• The intravenous form of Sarclisa was first approved in 2020.

The U.S. Food and Drug Administration has approved a wearable injector form of Sanofi's blood cancer drug, Sarclisa, providing an alternative to intravenous infusions for patients with multiple myeloma. The new formulation, Sarclisa Escena, utilizes an on-body injector device for subcutaneous delivery.